What does BLA stand for?

Biologic License Application (US FDA)

This definition appears very rarely and is found in the following Acronym Finder categories:

Military and Government
Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Basic Living Allowance (various organizations) Basic Loan Agreement Basilian Lay Associate (Toronto, ON, Canada) Basolateral Amygdala Bath Leadership Academy (UK) Battle for Lion's Arch (gaming) Best Linear Approximation Better Left Alone Bidirectional Line Amplifier Bill Low and Associates (Abbotsford, BC, Canada)		Biologics License Agreement (US FDA) Black Lawyer Association Black Liberation Army Black Lung Association Blocking Acknowledgement (ITU-T) Blocks Lactic Acid Blood Loss Anemia Board of Landscape Architects (various locations) Boating Law Administrator Boston Latin Academy

Samples in periodicals archive:

Food and Drug Administration (FDA) has accepted, for filing and review, the company's submission of a biologic license application for belatacept, which is in ongoing phase III development for use in kidney transplantation.

United States : Bristol-Myers Squibb Announces Acceptance Of ...

The revision should not affect the overall time it takes the FDA to review new or generic drug applications or biologic license applications, the agency said.

FDA rejects 'approvable,' 'not approvable' terms

Nabi Biopharmaceuticals, Boca Raton, FL, announced the Blood Products Advisory Committee (BPAC) of the US Food and Drug Administration (FDA) voted to recommend approval of the company's Biologic License Application (BLA) for Nabi-HB Intravenous (Hepatitis B Immune Globulin (Human) Intravenous).

Nabi gets positive opinion from FDA panel for injectable hepatitis B ...

The company is gathering data from a Phase III investigational trial for the treatment of non-Hodgkin's lymphoma and intends to file a Biologic License Application for Bexxar by the end of 1998.

Coulter Pharmaceutical Announces Exercise of Over-Allotment Option

The company is gathering data from a Phase III investigational trial for the treatment of non-Hodgkin's lymphoma and intends to file a Biologic License Application for Bexxar by the end of 1998.

Coulter Pharmaceutical Offers 2.4 Million Shares of Common Stock At ...

The company is gathering data from a Phase III investigational trial for the treatment of non-Hodgkin's lymphoma and intends to file a Biologic License Application for Bexxar by the end of 1998.

Coulter Pharmaceutical Offers 2.4 Million Shares of Common Stock At ...

We expect to file a Biologic License Application (BLA) shortly thereafter.

Palatin Corrects and Replaces Earlier Release